As Eisai, Biogen plot a course to accelerated approvals for Alzheimer’s drug, a mob of skeptics are waiting to decipher hard numbers
Welcome to the big catalyst of Q3.
Eisai and Biogen won’t reveal their data from a mid-stage study of BAN2401 in Alzheimer’s disease until tomorrow, but there’s no question that they’re presenting this as a major breakthrough in the field that needs to be hustled to patients as rapidly as possible.
Now they just have to convince a legion of practiced, longtime skeptics that they’re right.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
